Aveo Oncology said the FDA will complete a review of its cancer pill Tivopath by July 28. Aveo, which is based in Cambridge, and its partner Astellas Pharma Inc. want to market Tivopath as a treatment for advanced kidney cancer. The companies said the FDA accepted their application, and the agency will conduct a standard 10-month review. Astellas will pay Aveo $15 million now that the filing has been accepted.